Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
Canadian HIV Trials Network, Vancouver, British Columbia, Canada.
JAMA. 2022 May 24;327(20):1983-1991. doi: 10.1001/jama.2022.5906.
There are limited high-quality, population-level data about the effect of SARS-CoV-2 infection on pregnancy using contemporaneous comparator cohorts.
To describe maternal and perinatal outcomes associated with SARS-CoV-2 infection in pregnancy and to assess variables associated with severe disease in the pregnant population.
DESIGN, SETTING, AND PARTICIPANTS: CANCOVID-Preg is an observational surveillance program for SARS-CoV-2-affected pregnancies in Canada. This analysis presents exploratory, population-level data from 6 Canadian provinces for the period of March 1, 2020, to October 31, 2021. A total of 6012 pregnant persons with a positive SARS-CoV-2 polymerase chain reaction test result at any time in pregnancy (primarily due to symptomatic presentation) were included and compared with 2 contemporaneous groups including age-matched female individuals with SARS-CoV-2 and unaffected pregnant persons from the pandemic time period.
SARS-CoV-2 infection during pregnancy. Incident infections in pregnancy were reported to CANCOVID-Preg by participating provinces/territories.
Maternal and perinatal outcomes associated with SARS-CoV-2 infection as well as risk factors for severe disease (ie, disease requiring hospitalization, admission to an intensive care unit/critical care unit, and/or oxygen therapy).
Among 6012 pregnant individuals with SARS-CoV-2 in Canada (median age, 31 [IQR, 28-35] years), the greatest proportion of cases were diagnosed at 28 to 37 weeks' gestation (35.7%). Non-White individuals were disproportionately represented. Being pregnant was associated with a significantly increased risk of SARS-CoV-2-related hospitalization compared with SARS-CoV-2 cases among all women aged 20 to 49 years in the general population of Canada (7.75% vs 2.93%; relative risk, 2.65 [95% CI, 2.41-2.88]) as well as an increased risk of intensive care unit/critical care unit admission (2.01% vs 0.37%; relative risk, 5.46 [95% CI, 4.50-6.53]). Increasing age, preexisting hypertension, and greater gestational age at diagnosis were significantly associated with worse maternal outcomes. The risk of preterm birth was significantly elevated among SARS-CoV-2-affected pregnancies (11.05% vs 6.76%; relative risk, 1.63 [95% CI, 1.52-1.76]), even in cases of milder disease not requiring hospitalization, compared with unaffected pregnancies during the same time period.
In this exploratory surveillance study conducted in Canada from March 2020 to October 2021, SARS-CoV-2 infection during pregnancy was significantly associated with increased risk of adverse maternal outcomes and preterm birth.
目前关于使用同期对照队列的 SARS-CoV-2 感染对妊娠影响的高质量、人群水平数据有限。
描述与 SARS-CoV-2 感染相关的妊娠期间的孕产妇和围产期结局,并评估与妊娠人群中严重疾病相关的变量。
设计、地点和参与者:CANCOVID-Preg 是加拿大针对 SARS-CoV-2 感染妊娠的观察性监测计划。本分析报告了 2020 年 3 月 1 日至 2021 年 10 月 31 日期间加拿大 6 个省的探索性、人群水平数据。共有 6012 名在妊娠期间任何时候 SARS-CoV-2 聚合酶链反应检测结果呈阳性的孕妇(主要是由于出现症状)被纳入研究,并与同期的 2 个组进行了比较,包括年龄匹配的 SARS-CoV-2 女性个体和流行期间未受感染的孕妇。
妊娠期间的 SARS-CoV-2 感染。参与省/地区向 CANCOVID-Preg 报告妊娠期间的感染病例。
与 SARS-CoV-2 感染相关的孕产妇和围产期结局以及严重疾病的危险因素(即需要住院治疗、入住重症监护病房/重症监护病房和/或吸氧治疗)。
在加拿大的 6012 名感染 SARS-CoV-2 的孕妇中(中位数年龄为 31 [IQR,28-35] 岁),最大比例的病例发生在 28 至 37 孕周(35.7%)。非白种人比例不成比例。与加拿大 20 至 49 岁所有女性中的 SARS-CoV-2 病例相比,妊娠与 SARS-CoV-2 相关住院的风险显著增加(7.75% vs 2.93%;相对风险,2.65 [95%CI,2.41-2.88]),与重症监护病房/重症监护病房入院的风险增加相关(2.01% vs 0.37%;相对风险,5.46 [95%CI,4.50-6.53])。年龄增长、高血压和诊断时的妊娠周数增加与孕产妇结局恶化显著相关。与同期未受感染的妊娠相比,SARS-CoV-2 感染妊娠的早产风险显著升高(11.05% vs 6.76%;相对风险,1.63 [95%CI,1.52-1.76]),即使是在不需要住院治疗的轻度疾病病例中也是如此。
在这项于 2020 年 3 月至 2021 年 10 月期间在加拿大进行的探索性监测研究中,妊娠期间的 SARS-CoV-2 感染与不良孕产妇结局和早产的风险增加显著相关。